ResearcherPeking UniversityActive in the last 2 years

Xiaoyan Qiu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6371-2062; OpenAlex author ID A5100766385. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. Last author DOI 10.1016/j.xcrm.2026.102660 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yupei Zhao · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Quan Liao · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Ming Cui · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Xiaoding Liu · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗
Shenghua Zhang · 1 shared paper, 2026 · strength 0.26
- Paper Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic… DOI 10.1016/j.xcrm.2026.102660 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.